Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19

• Status: Completed
• Trial end date: 2021-04-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if Quercetin Phytosome is beneficial for the treatment of COVID-19.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Liaquat University of Medical & Health Sciences
• Collaborators: Dow University of Health Sciences; University of Milano Bicocca; University of Oxford; University of Pavia
• Treatments: Quercetin

Criteria

Inclusion Criteria:

• Age ≥ 18 years of either gender

• Confirmed SARS-CoV-2 infection by RT-PCR

• Currently diagnosed with mild-to-moderate symptoms of COVID-19 at home in self-isolation within 3 days of SARS-CoV-2 infection.

• Displaying typical symptoms of COVID-19 such as a high temperature, a new, continuous cough, a loss or change to sense of smell or taste

• Patients who have signed informed consent.

Exclusion Criteria:

• Patients with proven hypersensitivity or allergic reaction to quercetin

• Manifest contrary will